Transcriptomics

Dataset Information

0

RNA-seq of SARS-CoV-2-infected human primary hepatocyte-derived spheroids upon interferon a2 and baricitinib treatment


ABSTRACT: Biological replicates of liver spheroids derived from primary hepatocytes were treated with IFNa2 and/or baricitinib for 24 h and subsequently infected with Sars-CoV-2. The cells were harvested 48 h time after infection. Total RNA was extracted and sequenced with a strand-specific paired end RNA-seq protocol.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Homo sapiens  

SUBMITTER: Christian Sommerauer   Claudia Kutter  

PROVIDER: E-MTAB-9711 | ArrayExpress | 2020-11-18

SECONDARY ACCESSION(S): ERP124749

REPOSITORIES: ArrayExpress, ENA

altmetric image

Publications

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.

Stebbing Justin J   Sánchez Nievas Ginés G   Falcone Marco M   Youhanna Sonia S   Richardson Peter P   Ottaviani Silvia S   Shen Joanne X JX   Sommerauer Christian C   Tiseo Giusy G   Ghiadoni Lorenzo L   Virdis Agostino A   Monzani Fabio F   Rizos Luis Romero LR   Forfori Francesco F   Avendaño-Céspedes Almudena A   De Marco Salvatore S   Carrozzi Laura L   Lena Fabio F   Sánchez-Jurado Pedro Manuel PM   Lacerenza Leonardo Gianluca LG   Cesira Nencioni N   Caldevilla-Bernardo David D   Perrella Antonio A   Niccoli Laura L   Méndez Lourdes Sáez LS   Matarrese Daniela D   Goletti Delia D   Tan Yee-Joo YJ   Monteil Vanessa V   Dranitsaris George G   Cantini Fabrizio F   Farcomeni Alessio A   Dutta Shuchismita S   Burley Stephen K SK   Zhang Haibo H   Pistello Mauro M   Li William W   Mas Romero Marta M   Andrés Pretel Fernando F   Simón-Talero Rafaela Sánchez RS   García-Molina Rafael R   Kutter Claudia C   Felce James H JH   Nizami Zehra F ZF   Miklosi Andras G AG   Penninger Josef M JM   Menichetti Francesco F   Mirazimi Ali A   Abizanda Pedro P   Lauschke Volker M VM  

Science advances 20201113


Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show a 71% (95% CI 0.15-0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age 81 years). A further 48 cases with mild-moderate pneumonia recovered uneventfully. Using organotypic 3D cultures of primary human liver cells, we demonstrate that interferon-alpha-2 (IFNα2) significantly increases ACE  ...[more]

Similar Datasets

2019-01-01 | S-EPMC6618316 | BioStudies
2017-01-01 | S-EPMC6402191 | BioStudies
2020-01-01 | S-EPMC7300657 | BioStudies
2018-01-01 | S-EPMC6587754 | BioStudies
2020-01-01 | S-EPMC7523106 | BioStudies
1000-01-01 | S-EPMC6251844 | BioStudies
2017-01-01 | S-EPMC5347954 | BioStudies
2017-01-01 | S-EPMC5264214 | BioStudies
2019-01-01 | S-EPMC6764124 | BioStudies
2020-01-01 | S-EPMC7410892 | BioStudies